PursueCare to Spotlight Next-Gen Digital Therapeutics at the 56th American Society of Addiction Medicine (ASAM) Conference in Denver April 24-27

Celebrates ASAM Distinguished Fellow Honor for Dr. Jason Kirby

PursueCare, a leading provider of virtual addiction treatment and specialized pharmacy services, is proud to announce its participation in the 56th Annual American Society of Addiction Medicine (ASAM) Conference in Denver, Colo., April 24-27, 2025. The event gathers top experts, clinicians, and innovators in addiction medicine to advance science, practice, and policy in the field.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250421565215/en/

Dr. Jason Kirby, DO, MBA, DFASAM, Medical Director - ASAM 2025 Distinguished Fellow

Honoring a Visionary in Addiction Medicine—Dr. Jason Kirby Named 2025 ASAM Distinguished Fellow

PursueCare’s Medical Director, Dr. Jason Kirby, DO, MBA, DFASAM, has been named a 2025 Distinguished Fellow of ASAM, one of the society’s highest honors. This prestigious designation recognizes Dr. Kirby’s enduring commitment to evidence-based, outcomes-driven care and his leadership in improving access to treatment for individuals with substance use disorder (SUD).

“I began this journey nearly a decade ago with a mission to provide compassionate, science-backed care for people living with addiction. Being recognized as a Distinguished Fellow by ASAM is a profound honor,” said Dr. Kirby. “It’s a privilege to stand alongside so many esteemed leaders who are transforming the future of addiction medicine.”

With dual board certifications in addiction medicine and family medicine, and deep expertise in healthcare policy and population health, Dr. Kirby exemplifies the innovative and empathetic leadership PursueCare brings to the field.

Visit PursueCare at Booth #325—Experience RESET® and RESET-O®

Conference attendees are invited to Booth #325 to experience PursueCare’s cutting-edge, virtual-first addiction treatment platform. The company will spotlight its latest advancements, including:

• RESET® and RESET-O®—the first and only FDA-authorized digital therapeutics for SUD and opioid use disorder (OUD). Watch the video Transforming Addiction Treatment with RESET®.

• Tools that offer 24/7 recovery support, blending cognitive behavioral therapy (CBT), contingency management, and real-time progress tracking within PursueCare’s secure, proprietary smartphone applications.

These groundbreaking therapeutics are seamlessly embedded into PursueCare’s care model, extending the reach and impact of virtual addiction care.

Elevating the Standards of Recovery

“Dr. Kirby’s recognition as a Distinguished Fellow is a proud moment for everyone at PursueCare,” said Nick Mercadante, Founder and Chief Executive Officer. “His tireless work to expand access and improve outcomes in virtual addiction treatment reflects our mission to reimagine what recovery looks like for people everywhere.” With innovation at its core, PursueCare continues to lead the charge in transforming addiction care through accessible, scalable, and data-driven solutions.

About PursueCare

PursueCare provides personalized virtual addiction treatment for individuals across states (CT, KY, MA, ME, NH, OH, and WV). Our mission is to increase access to chronic care through telehealth. Patients engage with a multi-disciplinary team providing medical care, counseling, psychiatry, and pharmacy. FDA-authorized digital cognitive behavioral therapy, RESET® and RESET-O®, supports recovery 24/7. We accept private insurance, Medicare, and Medicaid.

Learn more at www.pursuecare.com and www.reachforreset.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250421565215/en/

With innovation at its core, PursueCare continues to lead the charge in transforming addiction care through accessible, scalable, and data-driven solutions.